1. Pentoxifylline: not just for alcoholic hepatitis anymore?

   • Roman E. Perri
   • Vijay H. Shah

   Editorial 08 April 2008 Pages: 137 - 139

2. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B

   • Teerha Piratvisuth

   Review Article 04 March 2008 Pages: 140 - 146

3. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure

   • Stephen Locarnini

   Review Article 28 March 2008 Pages: 147 - 151

   

4. Hepatitis B reactivation after chemotherapy: two decades of clinical research

   • George K. K. Lau

   HBV (Clinical & Basic) 05 March 2008 Pages: 152 - 162

   

5. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

   • Nancy Leung

   Review Article 04 March 2008 Pages: 163 - 178

6. Should chronic HBV infected patients with normal ALT treated: debate

   • Shiv Kumar Sarin
   • Manoj Kumar

   Review article 04 March 2008 Pages: 179 - 184

7. Chronic HBV infection with persistently normal ALT b. not to treat

   • Kwang-Hyub Han
   • Do Young Kim

   Others (Announcements, etc.) 06 March 2008 Pages: 185 - 189

8. Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors

   • Wing-Kin Syn
   • Peter Nightingale
   • Jeffrey M. Bateman

   Original Article 28 February 2008 Pages: 190 - 195

9. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)

   • Yin-Mei Lee
   • Dede S. Sutedja
   • Seng-Gee Lim

   NASH (NAFLD), PHT, Hepatic Failure and Others 28 February 2008 Pages: 196 - 201

   

10. Comparative redox status in alcoholic liver disease and nonalcoholic fatty liver disease

    • Payal Bhardwaj
    • Kaushal Madan
    • Anoop Saraya

    NASH (NAFLD), PHT, Hepatic Failure and Others 27 February 2008 Pages: 202 - 208

    

11. Advanced hepatic fibrosis and cirrhosis due to nonalcoholic fatty liver disease in Sri Lankan children: a preliminary report

    • S. Rajindrajith
    • A. S. Dassanayake
    • H. J. de Silva

    NASH (NAFLD), PHT, Hepatic Failure and Others 27 February 2008 Pages: 209 - 212

    

12. Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis

    • Norimasa Miura
    • Hiroko Kabashima
    • Goshi Shiota

    ORIGINAL ARTICLE 09 April 2008 Pages: 213 - 221

    

13. Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers

    • Minoru Nakamura
    • Kenji Funami
    • Tsukasa Seya

    Original Article 26 March 2008 Pages: 222 - 230

    

14. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India

    • Shashi Bala Paul
    • Vishnubhatla Sreenivas
    • Subrat Kumar Acharya

    Original Article 27 February 2008 Pages: 231 - 236

15. Prognostic analysis of pulmonary metastases from hepatocellular carcinoma

    • Shu-Min Zhang
    • Zhao-Chong Zeng
    • Bo-Heng Zhang

    Original Article 15 March 2008 Pages: 237 - 243

    

16. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)

    • Hie-Won Hann
    • Hee Bok Chae
    • Stephen R. Dunn

    Original Article 28 February 2008 Pages: 244 - 249

    

17. Metabolic profiles in patients with chronic hepatitis C: a case–control study

    • Ching-Sheng Hsu
    • Chun-Jen Liu
    • Jia-Horng Kao

    Original Article 28 February 2008 Pages: 250 - 257

18. Spontaneous rupture of metastatic α-fetoprotein-producing gastric cancer of the liver

    • Tetsuro Sohda
    • Takayuki Hanano
    • Shotaro Sakisaka

    Case Report Open access 08 April 2008 Pages: 258 - 261